By Federico Cappuzzo
This textual content is a concise and updated evaluation, which discusses the heritage, improvement and mechanisms of resistance, checking out equipment and know-how, present and rising cures and assets that clinicians provides to their sufferers. Busy healthcare execs who need a quickly overview of remedy resistance in lung melanoma in addition to a precis of present treatments will make the most of this succinct guide.
Read or Download Guide to Targeted Therapies: Treatment Resistance in Lung Cancer PDF
Best cancer books
Cancer Cell Culture: Methods and Protocols
With many contemporary advances, melanoma mobile tradition learn is extra very important than ever sooner than. This well timed version of melanoma telephone tradition: tools and Protocols covers the fundamental thoughts of melanoma cellphone biology and tradition whereas increasing upon the hot shift in telephone tradition tools from the iteration of recent cellphone traces to using fundamental cells.
Die tierische Zelle in Zellkultur
Die ersten erfolgreichen Versuche zur Züchtung tierischer Zellen außerhalb des Organismus reichen zurück in den Beginn unseres Jahrhunderts. 1907 gelang HARRI SON durch Explantation von Gewebsstücken aus Froschembryonen der Nachweis, daß in der Embryonalentwicklung die Neuriten als Fortsätze der Nervenzelle ohne Be teiligung anderer Zellen gebildet werden, und daß damit eine spezifische celluläre Funktion auch außerhalb des Gesamtorganismus zu beobachten ist [310,311].
Port-Site and Wound Recurrences in Cancer Surgery: Incidence - Pathogenesis - Prevention
In past times nine years, stories of 'port-site' deposits following laparoscopic surgical procedure for malignancy, specifically laparoscopic resection of colonic melanoma, have forged a shadow at the knowledge of the laparoscopic process within the surgical guy agement in sufferers with melanoma. these reviews of port-site deposits, a few ninety instances stated within the literature as much as 1999, have opened a 'can of worms' and highlighted the shortage of our wisdom on melanoma mobilephone migration from reliable tu mors and the criteria that underlie their profitable implantation in surgical wounds either within the presence and shortage of a good strain pneumoperito neum.
- Role of the Transcriptome in Breast Cancer Prevention
- Imaging of Male Breast Cancer
- Free from fear
- Breast Reconstruction with Autologous Tissue Art and Artistry
- Advances in Breast Cancer Management, Second Edition
Extra info for Guide to Targeted Therapies: Treatment Resistance in Lung Cancer
Example text
Clin Cancer Res. 2006;12:5764-5910. 20 Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013;19:2240-2710. 21 Yun CH, Mengwasser KE, Toms AV, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 2008;105:2070-2075. 36 • GUID E TO TA R G E TE D THE R A P IE S: T RE AT M E N T RE S IS TA N CE IN LU N G C AN C E R 22 Engelman JA, Zejnullahu K, Mitsudomi T, et al.
T H E R A P Y O P T I O N S F O R A D VA N C E D N S C LC • 25 67 Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALKpositive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012;13:1011-1019. 68 Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALKpositive lung cancer. N Engl J Med, 2013; 368: 2385–94. 69 Mok T, Kim D-W, Wu Y-L, et al. First-line crizotinib versus pemetrexed–cisplatin or pemetrexed– carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014).
65 Tanizaki J, Okamoto I, Okamoto K, et al. MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations. J Thorac Oncol. 2011; 6:1624-1631. 66 Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363: 1693-1703. T H E R A P Y O P T I O N S F O R A D VA N C E D N S C LC • 25 67 Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALKpositive non-small-cell lung cancer: updated results from a phase 1 study.